APOA1 and Alzheimer disease: Others have administrated reconstituted HDL, recombinant apoA-I, and apoA-I mimetics to APP/PS1 or other AD model mice and similarly observed improvements in memory, neuroinflammation, and CAA, and some also observed reduced total soluble Aβ levels and Aβ deposition [39, 41–43].